HOME >> MEDICINE >> NEWS
$15M Northwestern grant funds heart research

CHICAGO --- An estimated 100,000 patients who have heart attacks each year are not eligible for life-saving beta-blocker drug therapy because their heart rates are too low. Beta-blockers improve survival rates up to 30 percent in people who have had heart attacks by helping to regulate the heartbeat.

Northwestern University's Feinberg School of Medicine has received a $15 million grant from the National Heart, Lung, and Blood Institute to conduct a national study investigating whether implanting a pacemaker in low-heart rate, heart-attack patients which will enable them to take beta-blockers -- will also improve survival.

Jeffrey Goldberger, M.D., professor of medicine at Feinberg and director of Cardiac Electrophysiology at Northwestern Memorial Hospital, is the national principal investigator of the multicenter, randomized clinical research study. The five-year study will enroll 1,124 participants from around the country.

Northwestern Memorial Hospital is the local site and will enroll 20 to 30 subjects. Other centers are in 27 states, including Michigan, Minnesota, Iowa, Wisconsin and Missouri.

"The study will also help us determine more precisely how frequently low heart rates are a problem in heart attack patients. The current estimates are 5 to 10 percent of 1.5 million heart attack patients yearly," Goldberger said.

Goldberger noted most of the participants in the study will be patients seen in the hospital after a heart attack. The name of the study is The PACE-MI TRIAL: Pacemaker and Beta-Blocker Therapy after Myocardial Infarction Trial (PACE-MI.)


'"/>

Contact: Marla Paul
marla-paul@northwestern.edu
312-503-8928
Northwestern University
6-Mar-2007


Page: 1

Related medicine news :

1. Northwestern chemists develop new method for synthesizing anti-cancer flavonoids
2. Northwestern surgeon invents teaching technology for scary patient exams
3. Northwestern Memorial earns magnet status for nursing excellence
4. Heart transplant program at Northwestern Memorial Hospital celebrates anniversary
5. Evanston Northwestern Healthcare first to use latest robotic surgical system
6. Northwestern researchers launch Avastin trial for pancreatic tumors
7. Northwestern Memorial Hospital named Bariatric Surgery Society Center of Excellence
8. Northwestern receives major award for nanotechnology cancer center
9. Northwestern Memorial named one of 100 Best Places for Working Mothers
10. Northwestern Memorial named among 100 Most Wired Hospitals for sixth consecutive year
11. Northwestern Memorial Hospital installs 64-Slice CT scanner, now available for clinical use

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Northwestern grant funds heart research

(Date:5/20/2013)... Horizon NJ Health, New Jersey’s largest ... it has earned a Commendable Accreditation status from ... Health is a wholly owned subsidiary of Horizon Blue ... Health Plan Accreditation is a nationally recognized program that ... plans provide to their members. Health Plan Accreditation performance ...
(Date:5/20/2013)... is proud to announce the publication of the much-anticipated ... A. Weinberg. , The First Edition has been ... the most important advances in the fast-growing field of ... all of its hallmark features admired by students, instructors, ... of Cancer is a textbook for students studying the ...
(Date:5/20/2013)... -- Although many hospital intensive care units have ... improve outcomes, new research suggests this may have ... of teaching hospitals in the United States and ... physician in the ICU, the practice may unnecessarily ... hospitals with fewer resources, the study authors said. ...
(Date:5/20/2013)... Hospital emergency departments play a growing role in the ... of hospital admissions and serving increasingly as an advanced ... new RAND Corporation study. , While often targeted as ... rooms remain an important safety net for Americans who ... in slowing the growth of health care costs, according ...
(Date:5/20/2013)... Nearly three out of four pregnant women ... pregnancies, a Loyola University Medical Center study has found. ... on pregnant women,s quality of life, the study found. ... and Payton Johnson was presented during the American Congress ... New Orleans. , One hundred and four pregnant women ...
Breaking Medicine News(10 mins):Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3Health News:'The Biology of Cancer' by Robert A. Weinberg 2Health News:Nighttime Docs at ICUs Don't Boost Patient Outcomes: Study 2Health News:Hospital emergency departments gaining in importance, study finds 2Health News:Hospital emergency departments gaining in importance, study finds 3Health News:72 percent of pregnant women experience constipation and other bowel problems 2
(Date:5/20/2013)... 2013  AbbVie (NYSE: ABBV ) ... clinical study called SONAR (Study Of Diabetic Nephropathy ... investigational compound atrasentan - when added to standard of ... with stage 2 to 4 chronic kidney disease ... large, multinational, double-blind, placebo-controlled clinical study that is ...
(Date:5/19/2013)... Calif. , May 20, 2013 Claret Medical, ... Nicolas Van Mieghem et al., ... . Published ahead of print in Circulation, May 7 th ... Erasmus Medical Center, Rotterdam, the Netherlands ... of the Cardiovascular Pathology Institute, Gaithersburg, Maryland.  ...
(Date:5/18/2013)... 18, 2013 Although colonoscopy exams prevent many ... most sensitive method for detecting colorectal cancers 2 , ... cases 3 . EndoChoice ® Inc. today unveiled ... improves the accuracy of this procedure and greatly reduces ... be discussing these clinical trial results and featuring the ...
Breaking Medicine Technology:AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3
Cached News: